Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study
PLOS One · 20.05.2026 · 21 (5) · e0347783
DOI: 10.1371/journal.pone.0347783 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift PLOS One, online erschienen am 20.05.2026. Verfasst von Touria Essayagh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hassan First University of Settat, Institut Supérieur des Sciences de la Santé, Laboratoire des Sciences et Ingénierie Biomédicales, Biophysique et S…. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Human Papillomavirus Viruses, Vaccination, Papillomavirus Infections. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The human papillomavirus (HPV) vaccine helps significantly reduce the incidence of cervical cancer. However, in many countries, its adoption remains limited. In this context, our study aimed to measure the prevalence of HPV vaccination hesitancy among young girls and to identify its associated risk factors.
Methods
From 10 th April to 30 th June 2025, a cross-sectional survey was conducted in Morocco among girls aged 11–14 attending middle school. Face-to-face interviews gathered sociodemographic data, HPV knowledge, and vaccination attitudes. Multivariate logistic regression identified risk variables for vaccine hesitancy.
Results
A total of 1,836 participants were collected with a mean age of 13.0 ± 0.8 years. The percentage of vaccine hesitancy reached 88.8%. The main risk factors were unvaccinated pairs (AOR = 11.78; CI [7.67–18.0]), paternal illiteracy (AOR = 7.67; [1.99–29.55]), low recommendation of the vaccine by health personnel (AOR = 4.14; [2.44–7.02]), belief that the vaccine promotes sexual activity (AOR = 3.10; [2.01–4.79]), insufficient knowledge of the target population (AOR = 2.51; [1.63–3.85]), perception of adverse effects (AOR = 1.97; [1.31–2.98]), insufficient knowledge of the number of doses required (AOR = 1.76; [1.06–2.92]), fear of vaccination (AOR = 1.71; [1.14–2.58]), fear of regretting vaccination (AOR = 1.55; [1.02–2.36]), and age (AOR = 1.34; [1.06–1.69]).
Conclusion
HPV vaccination hesitancy remains high and is shaped by social, educational, and cultural factors. These findings underscore the need for targeted educational initiatives and increased awareness among healthcare professionals. Integrating vaccination into school health programs may help improve uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hassan First University of Settat, Institut Supérieur des Sciences de la Santé, Laboratoire des Sciences et Ingénierie Biomédicales, Biophysique et Santé, Settat, Morocco.
- Office National de Sécurité Sanitaire des produits Alimentaires, Meknès, Morocco.
- National Infectious Diseases Hospital Laboratory, Kabul, Afghanistan.
- Hassan First University of Settat, Faculté des Sciences et Techniques, Laboratoire Agroalimentaire et Santé, Settat, Morocco.
ORCID-Profile: Rehmatullah Zadran
Zitieren
APA
Essayagh, T., Essayagh, M., Slibani, H., El Hachimi, S., Nmila, K., Addakiri, K., Zadran, R., & Essayagh, S. (2026). Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study. PLOS One, 21(5), e0347783. https://doi.org/10.1371/journal.pone.0347783
Vancouver
Essayagh T, Essayagh M, Slibani H, El Hachimi S, Nmila K, Addakiri K, et al. Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study. PLOS One. 2026;21(5):e0347783. doi:10.1371/journal.pone.0347783
BibTeX
@article{Essayagh2026,
author = {Essayagh, Touria and Essayagh, Meriem and Slibani, Housnia and El Hachimi, Soukayna and Nmila, Kaoutar and Addakiri, Khaoula and Zadran, Rehmatullah and Essayagh, Sanah},
title = {Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0347783},
doi = {10.1371/journal.pone.0347783}
}
EUVIMED